Invention Grant
US09128095B2 Diagnosis or prognosis of lung cancer and colorectal cancer based on expression level of glutaredoxin 3
有权
基于谷氧还蛋白3表达水平的肺癌和结肠直肠癌的诊断或预后
- Patent Title: Diagnosis or prognosis of lung cancer and colorectal cancer based on expression level of glutaredoxin 3
- Patent Title (中): 基于谷氧还蛋白3表达水平的肺癌和结肠直肠癌的诊断或预后
-
Application No.: US13259918Application Date: 2009-04-15
-
Publication No.: US09128095B2Publication Date: 2015-09-08
- Inventor: Il Han Kim
- Applicant: Il Han Kim
- Applicant Address: KR Daejeon
- Assignee: PAICHI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee: PAICHI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee Address: KR Daejeon
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: KR10-2009-0030364 20090408
- International Application: PCT/KR2009/001945 WO 20090415
- International Announcement: WO2010/123159 WO 20101028
- Main IPC: G01N1/00
- IPC: G01N1/00 ; G01N33/00 ; G01N33/48 ; G01N33/50 ; G01N33/53 ; G01N33/574 ; C12N9/02
Abstract:
The present invention relates to a biomarker for diagnosing lung cancer and colorectal cancer containing glutaredoxin 3 as an active ingredient, and a kit for diagnosing lung cancer and colorectal cancer using the same biomarker. Glutaredoxin 3 of the present invention is over-expressed in lung cancer tissue and colorectal cancer tissue, which enables early prediction of diagnosis or prognosis of lung cancer and colorectal cancer. Thus, glutaredoxin 3 can be helpfully used as a biomarker for diagnosing lung cancer and colorectal cancer.
Public/Granted literature
- US20120015847A1 DIAGNOSIS OR PROGNOSIS OF LUNG CANCER AND COLORECTAL CANCER BASED ON EXPRESSION LEVEL OF GLUTAREDOXIN 3 Public/Granted day:2012-01-19
Information query
